Zhongda Hospital Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2015
NCT02315495
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Jian-jun Yang | Jianjun Yang

Active Ingredients

Drugs in Phase 4 Trials (1)

dezocine (dalgan) (1 trial)

Drugs in Phase 3 Trials (2)

acarbose (precose) (1 trial)

saxagliptin (onglyza) (1 trial)

Drugs in Phase 2 Trials (2)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 5